Eton licenses LIBERVANT seizure treatment rights
- Eton Pharmaceuticals (NASDAQ:ETON) entered exclusive U.S. licensing and supply agreements with Aquestive Therapeutics for LIBERVANT, an investigational treatment for seizure clusters.
- The agreements cover the United States and its territories, with commercial availability targeted for April 2027 pending final FDA approval.
- LIBERVANT is a diazepam buccal film designed to treat seizure clusters in patients with epilepsy.
Eton Pharmaceuticals (NASDAQ:ETON) announced exclusive U.S. licensing and supply agreements with Aquestive Therapeutics (NASDAQ:AQST) for LIBERVANT, a seizure-cluster treatment.
The agreement provides Eton with commercialization rights for LIBERVANT across the United States and its territories.
The company expects potential commercial availability in April 2027, subject to final regulatory approval.
Eton plans to establish a dedicated neurology team to support the launch and commercialization of LIBERVANT.
LIBERVANT is a diazepam film administered inside the cheek and currently has tentative approval for patients with epilepsy ages 2 to 5 and 12 years and older.
Full approval for patients aged 12 and older could become available after VALTOCO’s orphan drug exclusivity expires on January 10, 2027.
The U.S. Food and Drug Administration is reviewing an application to expand LIBERVANT’s use to patients ages 6 to 11, with a target action date of March 29, 2027.
If approved, the potential label could expand to patients aged 6 and older.
LIBERVANT has received Orphan Drug Designation and has patent protection extending into 2038, with additional patent applications pending.
Eton Pharmaceuticals develops and commercializes treatments for rare diseases and other specialty healthcare needs.
